(Total Views: 450)
Posted On: 10/17/2020 4:02:22 PM
Post# of 1460
Another copy on when the medical field will know A2-73,
Fletch
falconer66a Saturday, 10/17/20 03:40:07 PM
Re: nidan7500 post# 276676 0
Post # of 276757
Attention will come.
Quote:
We have to find a way to get the right kind of attention.
Indeed. So far, Anavex Life Sciences Corp and its sigma-1 receptor agonist drugs are simply unknown, unrecognized to the vast majority of medical practitioners (those who prescribe drugs to patients — without prescriptions there are no sales, no income to Anavex).
Next time you are in the examining room with your physician, don't bother to ask him (or her) thoughts on Anavex. "Hey, doc, is this new Anavex drug of any use?" He'll give you a vacant glance and say nothing. He knows nothing about Anavex; has never heard of "blarcamesine." No articles about it in any of the medical literature he reads. No discussion of it in the physician's lounge. An unknown entity, altogether. For now, at least.
But how different will things be a year from now, when this blarcamesine drug has a) shown significant efficacies and safety in the treatment of Parkinson's disease, b) has begun to provide useful treatment outcomes for girls with Rett syndrome, and c) finally, gives far better treatment results for Alzheimer's, compared to the weak standard of care drugs now on pharmacy shelves?
Any one of those results, alone, when they therapeutically start to appear next year, will create real interest among physicians. But the real deal will be that a single drug, blarcamesine, produces favorable treatment outcomes for three very different central nervous system diseases. Even a first-year medical school student would find that extremely interesting; worthy of explanation. How, exactly, could a single drug provide positive treatment results for three very different CNS diseases? Specifically, what could be the mechanism of action at work in all three?
Here, those of us who have scrutinized the pre-clinical studies of the molecular and cellular biology of blarcamesine understand it's unique activation of the sigma-1 receptor protein, and how that then facilitates, favorably modulates a diversity of "downstream" chemical pathways or cascades, facilitating normalized neuron homeostasis, etc. Presently, I have the good sense to not open a conversation about this with any of my several physicians. It would be a waste of time for both of us.
But, next year, with Parkinson's patients getting their dementia prevented or suppressed, and girls with Rett syndrome beginning to lead more normalized lives, and thousands of people with Alzheimer's showing increased, more normalized cognition, blarcamesine and Anavex will be known to not only medical specialists, but to anyone with an interest in public health.
Then, new clinical studies of Anavex 3-71 will be undertaken. Skepticism about its putative safety and efficacy may be rather absent.
https://investorshub.advfn.com/boards/read_ms...=158961949
Fletch
falconer66a Saturday, 10/17/20 03:40:07 PM
Re: nidan7500 post# 276676 0
Post # of 276757
Attention will come.
Quote:
We have to find a way to get the right kind of attention.
Indeed. So far, Anavex Life Sciences Corp and its sigma-1 receptor agonist drugs are simply unknown, unrecognized to the vast majority of medical practitioners (those who prescribe drugs to patients — without prescriptions there are no sales, no income to Anavex).
Next time you are in the examining room with your physician, don't bother to ask him (or her) thoughts on Anavex. "Hey, doc, is this new Anavex drug of any use?" He'll give you a vacant glance and say nothing. He knows nothing about Anavex; has never heard of "blarcamesine." No articles about it in any of the medical literature he reads. No discussion of it in the physician's lounge. An unknown entity, altogether. For now, at least.
But how different will things be a year from now, when this blarcamesine drug has a) shown significant efficacies and safety in the treatment of Parkinson's disease, b) has begun to provide useful treatment outcomes for girls with Rett syndrome, and c) finally, gives far better treatment results for Alzheimer's, compared to the weak standard of care drugs now on pharmacy shelves?
Any one of those results, alone, when they therapeutically start to appear next year, will create real interest among physicians. But the real deal will be that a single drug, blarcamesine, produces favorable treatment outcomes for three very different central nervous system diseases. Even a first-year medical school student would find that extremely interesting; worthy of explanation. How, exactly, could a single drug provide positive treatment results for three very different CNS diseases? Specifically, what could be the mechanism of action at work in all three?
Here, those of us who have scrutinized the pre-clinical studies of the molecular and cellular biology of blarcamesine understand it's unique activation of the sigma-1 receptor protein, and how that then facilitates, favorably modulates a diversity of "downstream" chemical pathways or cascades, facilitating normalized neuron homeostasis, etc. Presently, I have the good sense to not open a conversation about this with any of my several physicians. It would be a waste of time for both of us.
But, next year, with Parkinson's patients getting their dementia prevented or suppressed, and girls with Rett syndrome beginning to lead more normalized lives, and thousands of people with Alzheimer's showing increased, more normalized cognition, blarcamesine and Anavex will be known to not only medical specialists, but to anyone with an interest in public health.
Then, new clinical studies of Anavex 3-71 will be undertaken. Skepticism about its putative safety and efficacy may be rather absent.
https://investorshub.advfn.com/boards/read_ms...=158961949
(1)
(0)Scroll down for more posts ▼
